Probe and kit for detecting fetal free DNA beta-thalassemia mutation in maternal blood

Abstract

The invention provides a probe and kit for detecting fetal free DNA beta-thalassemia mutation in maternal blood. The kit comprises a detection probe, a capture probe, a reaction film strip, a target gene amplification reagent, a cleaning solution, an incubation solution and a developing solution. According to the kit, a dot blot hybridization method is utilized; in the method, a DNA hybridizationprocess is used for detecting a product; and the kit has the advantages of simplicity in operation, rapidness, simplicity, convenience, small sample dosage, intuitive and reliable result and the like,and can be widely applied to detection of fetal free DNA beta-thalassemia mutation in maternal plasma in noninvasive prenatal diagnosis.

Description

technical field [0001] The invention belongs to the field of biotechnology, and in particular relates to a probe and a kit for detecting the mutation of fetal free DNA β-thalassemia in maternal blood. Background technique [0002] In 1997, the study found that there is free fetal DNA (cffDNA) in maternal plasma. This discovery opened up a new way for non-invasive prenatal diagnosis, especially in the diagnosis of single-gene genetic diseases, for the prevention of birth defects cffDNA Testing is critical. The current cffDNA detection of β-thalassemia mutations reported in the literature is mainly based on the specific genes on the Y chromosome in male embryos, so as to obtain the content of cffDNA in maternal plasma. Different genetic polymorphisms of nucleotide sequences can be used to identify fetal DNA, but due to the complexity of the experiment and the high requirements of the experimental conditions, it is difficult to apply it clinically. [0003] Advances in epigen...

AI Technical Summary

Problems solved by technology

[0004] However, the combination of dot blot hybridization and DNA methylation differen

Images